Denda A, Tang Q, Endoh T, Tsujiuchi T, Horiguchi K, Noguchi O, Mizumoto Y, Nakae D, Konishi Y
Department of Oncological Pathology, Nara Medical University, Japan.
Carcinogenesis. 1994 Jun;15(6):1279-83. doi: 10.1093/carcin/15.6.1279.
Effects of acetylsalicylic acid (ASA) (aspirin) on the pathogenesis of fatty liver, cirrhosis and hepatocarcinogenesis caused by a choline-deficient L-amino acid-defined (CDAA) diet were examined in male Fischer 344 rats fed a CDAA diet supplemented with 0, 0.1, 0.2, 0.4 or 0.8% ASA for 30 weeks. ASA at concentrations of > 0.2% prevented the development of both cirrhosis and preneoplastic and neoplastic nodules, but without any directly associated prevention of fatty changes. ASA also prevented hepatocyte proliferation and the generation of thiobarbituric acid-reactive substances and 8-hydroxydeoxyguanosine caused by feeding the CDAA diet, analyzed, respectively, after 1, 12 and 12 weeks. The results clearly indicate that the anti-inflammatory drug ASA, which is not a lipotropic factor, can prevent the pathogenesis of cirrhosis and hepatocarcinogenesis caused by a CDAA diet, which is possibly partly associated with the prevention of reactive oxygen species production.
在以胆碱缺乏的L-氨基酸限定(CDAA)饮食喂养30周,并补充0、0.1、0.2、0.4或0.8%乙酰水杨酸(ASA,阿司匹林)的雄性Fischer 344大鼠中,研究了ASA对由CDAA饮食引起的脂肪肝、肝硬化和肝癌发生机制的影响。浓度>0.2%的ASA可预防肝硬化以及癌前和肿瘤结节的形成,但并未直接预防脂肪变性。ASA还可预防CDAA饮食引起的肝细胞增殖以及丙二醛反应性物质和8-羟基脱氧鸟苷的生成,分别在喂养1、12和12周后进行分析。结果清楚地表明,抗炎药物ASA并非促脂因子,却可预防由CDAA饮食引起的肝硬化和肝癌发生,这可能部分与预防活性氧生成有关。